Home > Publications database > Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins > print

001     449052
005     20250716152033.0
024 7 _ |a 10.3390/pharmaceutics12020106
|2 doi
024 7 _ |a 10.3204/PUBDB-2020-03577
|2 datacite_doi
024 7 _ |a pmid:32013056
|2 pmid
024 7 _ |a WOS:000519268500076
|2 WOS
024 7 _ |a altmetric:118850893
|2 altmetric
024 7 _ |2 openalex
|a openalex:W3003533868
037 _ _ |a PUBDB-2020-03577
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Janisova, Larisa
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
260 _ _ |a Basel
|c 2020
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1601038546_17073
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma—namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1—using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery.
536 _ _ |a 6G3 - PETRA III (POF3-622)
|0 G:(DE-HGF)POF3-6G3
|c POF3-622
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
693 _ _ |a PETRA III
|f PETRA Beamline P12
|1 EXP:(DE-H253)PETRAIII-20150101
|0 EXP:(DE-H253)P-P12-20150101
|6 EXP:(DE-H253)P-P12-20150101
|x 0
700 1 _ |a Gruzinov, Andrey
|0 0000-0001-8598-5491
|b 1
700 1 _ |a Zaborova, Olga V.
|0 0000-0003-1646-9981
|b 2
700 1 _ |a Velychkivska, Nadiia
|0 0000-0002-4950-1071
|b 3
700 1 _ |a Vaněk, Ondřej
|0 0000-0003-1190-8535
|b 4
700 1 _ |a Chytil, Petr
|0 0000-0002-7135-9796
|b 5
700 1 _ |a Etrych, Tomáš
|0 0000-0001-5908-5182
|b 6
700 1 _ |a Janoušková, Olga
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Zhang, Xiaohan
|b 8
700 1 _ |a Blanchet, Clement
|0 P:(DE-H253)PIP1009408
|b 9
700 1 _ |a Papadakis, Christine M.
|0 0000-0002-7098-3458
|b 10
700 1 _ |a Svergun, Dmitri I.
|0 P:(DE-H253)PIP1001422
|b 11
700 1 _ |a Filippov, Sergey K.
|0 0000-0002-4253-5076
|b 12
773 _ _ |a 10.3390/pharmaceutics12020106
|g Vol. 12, no. 2, p. 106 -
|0 PERI:(DE-600)2527217-2
|n 2
|p 1-9
|t Pharmaceutics
|v 12
|y 2020
|x 1999-4923
856 4 _ |u https://www.mdpi.com/1999-4923/12/2/106
856 4 _ |u https://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.pdf
|y OpenAccess
856 4 _ |u https://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.gif?subformat=icon
|x icon
|y OpenAccess
856 4 _ |u https://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.jpg?subformat=icon-1440
|x icon-1440
|y OpenAccess
856 4 _ |u https://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
856 4 _ |u https://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:bib-pubdb1.desy.de:449052
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a European Molecular Biology Laboratory
|0 I:(DE-588b)235011-7
|k EMBL
|b 9
|6 P:(DE-H253)PIP1009408
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-H253)PIP1009408
910 1 _ |a European Molecular Biology Laboratory
|0 I:(DE-588b)235011-7
|k EMBL
|b 11
|6 P:(DE-H253)PIP1001422
913 1 _ |a DE-HGF
|b Forschungsbereich Materie
|l Von Materie zu Materialien und Leben
|1 G:(DE-HGF)POF3-620
|0 G:(DE-HGF)POF3-622
|2 G:(DE-HGF)POF3-600
|v Facility topic: Research on Matter with Brilliant Light Sources
|9 G:(DE-HGF)POF3-6G3
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-01-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARMACEUTICS : 2018
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-01-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-10
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-01-10
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|f 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-10
920 1 _ |0 I:(DE-H253)EMBL-User-20120814
|k EMBL-User
|l EMBL-User
|x 0
920 1 _ |0 I:(DE-H253)EMBL-20120731
|k EMBL
|l EMBL
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-H253)EMBL-User-20120814
980 _ _ |a I:(DE-H253)EMBL-20120731
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21